加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$0.8777
−US$0.0025 · -0.28%
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
前收盘价
US$0.8777
−US$0.0025 · -0.28%
盘前
US$0.8777
US$0.00 · 0.00%
10月8日 7:13 ET
盘中时间采用ET。市场数据可能有所延迟。
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
日内区间
当前US$0.8777
52周区间
当前US$0.8777
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
59
多空交织
风险
69
高风险
动量
19
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
日内区间
当前US$0.8777
52周区间
当前US$0.8777
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.7万 USD | — | — | 8.6万 USD | — |
| 销货成本 | 84.4万 USD | 1.6万 USD | 1.5万 USD | 1.5万 USD | 7000 USD |
| 毛利 | −82.7万 USD | −1.6万 USD | −1.5万 USD | 7.1万 USD | −7000 USD |
| 研究与开发 | 113.6万 USD | 1170.5万 USD | 603.5万 USD | 442.2万 USD | 286万 USD |
| 销售、一般及管理费用 | 302.4万 USD | 295.2万 USD | 354.9万 USD | 444.7万 USD | 434.8万 USD |
| 营业费用 | 416万 USD | 1465.7万 USD | 958.4万 USD | 886.9万 USD | 720.8万 USD |
| 利息收入 | 12万 USD | 10.1万 USD | 40.6万 USD | 16万 USD | — |
| 利息支出 | 1万 USD | 1.4万 USD | 38.4万 USD | 6.1万 USD | 1万 USD |
| 折旧和摊销 | 77.4万 USD | 1.6万 USD | 1.5万 USD | 1.5万 USD | 7000 USD |
| 营业利润 | −498.7万 USD | −1467.3万 USD | −958.4万 USD | −886.9万 USD | −720.8万 USD |
| 净利润 | −483.8万 USD | −1458.8万 USD | −934.4万 USD | −879.2万 USD | −724.6万 USD |
公司数据更新于 2026年10月8日。
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
